A5024829452- Adenosine and Purinergic Signaling
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Educational and Social Studies
- Lung Cancer Research Studies
- Renal Transplantation Outcomes and Treatments
- Cancer therapeutics and mechanisms
- Educational Tools and Methods
- Pancreatic and Hepatic Oncology Research
- Online and Blended Learning
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Fondazione Pisa
2021
Amsterdam UMC Location Vrije Universiteit Amsterdam
2020-2021
Cancer Center Amsterdam
2021
University Medical Center
2021
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive tumor characterized by early invasiveness, rapid progression and resistance to treatment. For more than twenty years, gemcitabine has been the main therapy for PDAC both in palliative adjuvant setting. After introduction of FOLFIRINOX as upfront treatment metastatic disease, still commonly used combination with nab-paclitaxel alternative first-line regimen, well a monotherapy elderly patients unfit chemotherapy. As...
Background: Resistance to EGFR-TKIs constitutes a major challenge for the management of EGFR-mutated NSCLC, and recent evidence suggests that deregulation specific microRNAs (miRNAs) may influence resistance targeted agents. In this retrospective study, we explored role plasmatic miRNAs (miR-21, miR-27a miR-181a) as surrogate predicting EGFR-TKI performance in NSCLC patients. Methods: Plasma samples 39 advanced patients treated with were collected at different points time miRNA levels...